PATENT CLAIM ANALYSIS

Application Number: 15742867
Application Type: Utility
Filing Date: 2018-01
Publication Date: 2018-07
Patent Classification: ["514", "317000"]

Abstract:
The invention relates to antagonists of integrin α4 and their use in pharmaceutical compositions, primarily topically administered ophthalmic compositions. The pharmaceutical compositions are useful for treating ocular inflammatory conditions, such as dry eye disease, non-infectious uveitis (e.g., anterior, intermediate, posterior, pan-uveitis), non-infectious conjunctivitis, iritis, or scleritis in animals, and particularly mammals, including humans.

Claim (Index 14):
Use according to  claim 12  or  claim 13 , wherein the medicament is for use in combination with one or more additional therapeutic agents selected from the group consisting of (a) cyclosporin A; (b) a steroid selected from the group consisting of dexamethasone base, dexamethasone phosphate, difluprednate, fluocinolone, fluorometholone base, fluorometholone acetate, loteprednol, prednisolone acetate, prednisolone phosphate, rimexolone, and triamcinolone acetonide; (c) a non-steroidal anti-inflammatory agent selected from the group consisting of bromfenac, diclofenac, flurbiprofen, ketorolac, and nepafenac; and (d) an LFA-1 antagonist.

Metadata:
- Claim Count in Document: 26.0
- Percentile: 86.0
- Lexical Diversity: 1.38
- Patent Class: 514.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15676968', '13304292', '13601258', '15080893', '14857758']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8241151514150853
- 35 USC 102 Novelty (BERT): 0.5127559798709961
- Combined Prediction Score: 0.7929792342606764
- Mean Citation Score: 255.577264
- Max Citation Score: 266.30417
- Similarity Product: 162.7221180596006

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test